HOME >> MEDICINE >> NEWS
Tamoxifen for prevention of breast cancer encouraging results but risks still unclear

Early findings from a randomised trial investigating the effectiveness of tamoxifen to prevent breast cancer are reported in this week's issue of THE LANCET. Although tamoxifen reduced breast cancer incidence by a third compared with women given placebo, the authors of the study caution that it is still too early to fully assess the risk to benefit ratio of tamoxifen as a preventative strategy for breast cancer.

Tamoxifen is well known in its effect to decrease recurrence of (and death from) breast cancer; however, three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side-effects associated with tamoxifen is unclear.

Jack Cuzick from Cancer Research UK, lead investigator of the International Breast Cancer Intervention Study (IBIS-I) and colleagues undertook a double-blind placebo-controlled randomised trial of tamoxifen, 20 mg/day for 5 years, in around 7000 women from the UK, Europe, Australia and New Zealand who were aged 3570 years and who were at an increased risk of breast cancer (eg. They had a Family history of the disease or had a benign lesion associated with an increased risk of breast cancer).

The frequency of breast cancer was reduced by a third among Women given tamoxifen (69 breast cancers in 3578 women in the tamoxifen group and 101 breast cancers in 3566 in the placebo group). Endometrial cancer--considered to be increased by tamoxifen use--was doubled in the tamoxifen group (11 instances compared with 5 in the control group), but this increase was not statistically significant, and all cases were localised (stage 1) and curable by hysterectomy.

However, tamoxifen use was associated with more than a doubling in the risk of blood-clotting complications, especially after surgery or long periods of immobilisation. The investigators comment that the incre
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
12-Sep-2002


Page: 1 2

Related medicine news :

1. Tamoxifens risks similar in African American and white women
2. Tamoxifen and estrogen have similar effects on the brain
3. Tamoxifen found to increase risk of endometrial cancer
4. Views Of Tamoxifen And Synthetic Estrogen In Action Provide Clues For Designing Better Drugs
5. International breast cancer prevention study launches in the United States and Canada
6. Cavity prevention tips for pre-school age children
7. HIV and ID doctors oppose ideologically driven STI prevention policies
8. School-based smoking prevention programs ineffective
9. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
10. Mount Sinai stroke prevention trial published in JAMA
11. New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/2/2016)... Las Vegas, NV (PRWEB) , ... May 02, ... ... with Specialty Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award ... be determined based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy ...
(Date:5/2/2016)... ... 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced ... the cut. The WUGC is being held in London, England this year from June 18-25. ... men’s division, another gold in the women’s masters division, and a silver in the women’s ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a great time to ... , “If you are ready to have a baby, it’s best to get started ... Babies is your Personal Conception & Pregnancy Organizer, written for women who plan on ...
(Date:5/2/2016)... MO (PRWEB) , ... May 02, 2016 , ... ... a division of Permobil, recently completed two groundbreaking studies that determined that the ... mattresses – are critical in the prevention of pressure injuries, which are now ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) ... B Payment Model Could Transform the Pharma Landscape .” CMS recently proposed a test ... spend on provider-administered drugs while preserving care provided to beneficiaries. The webinar will review ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... FREMONT, Calif. , April 28, 2016 ... Enterprise Validation Lifecycle Management Solutions (VLMS) today ... products and services for sufferers of chronic ... management System to manage their corporate validation ... been seeking a software solution to manage ...
(Date:4/27/2016)... Mass., April 27, 2016  Hologic, Inc. (Nasdaq: ... financial results for the fiscal second quarter ended ... (EPS) of $0.24 increased 41.2%, and non-GAAP diluted ... million increased 5.8% on a reported basis, and ... "We posted another good quarter, highlighted by ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology:
Cached News: